• Regulatory: NorthStar and Vision-MR Diagnostic Catheter submitted for 510(k) approval with FDA, Human Factors Study completed
• Commercial: NorthStar commercially launched in Europe, inhouse catheter shaft manufacturing approved, growing European pipeline
• Financial: Cash receipts of $124k, operating cash outflows of $4.8m, $45.7m in total cash and short-term investments

Imricor Medical Systems, Inc. (ASX: IMR) released its Appendix 4C Quarterly Cash Flow Report for the period ended 30 September 2025 and provided an update on its operational performance. Key highlights include: Regulatory - NorthStar and Vision-MR Diagnostic Catheter submitted for 510(k) approval with the FDA, completion of Human Factors Study for FDA with approximately 20 hospitals participating. Commercial - Following CE Mark, NorthStar has been commercially launched in Europe at the end of the quarter, regulatory approval received from European Notified Body to bring inhouse catheter shaft manufacturing, European Pipeline continues to grow increasing from 26 to 35 during the quarter. Financial - Cash receipts of $124k temporarily impacted by customer sites enrolling VISABL-AFL patients which are non-revenue generating in the short term, operating cash outflows in Q3 of US$4.8m, total cash and short-term investments of US$45.7m vs US$50.3m as at 30 June 2025. The company remains focused on driving adoption, expanding its clinical trial footprint, and continuing to deliver on its vision of transforming cardiac ablation procedures worldwide.

The company reported cash receipts of $124k and operating cash outflows of $4.8m in Q3 CY25. Total cash and short-term investments stood at $45.7m at the end of the quarter.

Imricor is focused on driving adoption, expanding its clinical trial footprint, and continuing to deliver on its vision of transforming cardiac ablation procedures worldwide.